CEGX Back to portfolio


The TrueMethyl® Seq kit

Samples

DNA/protein in bar-coded sample tubes.

DNA

Nuclear transfer, pipette inserted into egg

Timeline

May 2012
Syncona meets with founders to review commercial opportunities for new method of sequencing novel base modification 5 hydroxymethylcytosine
August 2012
Syncona commits £500k in seed financing of the company
May 2016
Cambridge Epigenetix announces a $21m Series B investment by Google Ventures, Sequoia, New Science Ventures and Syncona

Company Details

Description

Diagnostic tools

Fully diluted ownership

12%

Value of Syncona holding

£5.2m

Description

CEGX’s disruptive epigenetics discovery platform enables the identification of sensitive and disease-specific marks from blood and tissue samples — enhancing human health through earlier diagnosis, improved patient stratification and the development of liquid biopsy-based tests.

CEO

Jason Mellad

Syncona Representatives
  • Martin Murphy
COO
  • Hayden Jeffreys